Analysis of CD8 + T cell response during the 2013–2016 Ebola epidemic in West Africa
2018; National Academy of Sciences; Volume: 115; Issue: 32 Linguagem: Inglês
10.1073/pnas.1806200115
ISSN1091-6490
AutoresSaori Sakabe, Brian M. Sullivan, Jessica N. Hartnett, Refugio Robles‐Sikisaka, Karthik Gangavarapu, Beatrice Cubitt, Brian C. Ware, Dylan Kotliar, Luis M. Branco, Augustine Goba, Mambu Momoh, John Demby Sandi, Lansana Kanneh, Donald S. Grant, Robert F. Garry, Kristian G. Andersen, Juan Carlos de la Torre, Pardis C. Sabeti, John S. Schieffelin, Michael B. A. Oldstone,
Tópico(s)COVID-19 epidemiological studies
ResumoSignificance Zaire ebolavirus (EBOV) is a viral pathogen of significant global health concern best exemplified by more than 28,000 human infections during the recent West African epidemic. Examining immunity in EBOV disease survivors has been historically difficult due to the occurrence of only small outbreaks in remote regions of central Africa. Consequently, little data exist describing EBOV-specific T cell responses during human infection. We examined virus-specific CD8 + T cell immunity in 32 Sierra Leonean survivors of the 2013–2016 epidemic. CD8 + T cells against the nucleoprotein dominated the EBOV-specific responses in this group, while a minority of individuals harbored memory CD8 + T cells against the EBOV-GP. Our data have implications in designing EBOV vaccines that can elicit cell-mediated immunity in a large group of individuals.
Referência(s)